公开(公告)号：US12123015B2

公开(公告)日：2024-10-22

申请号：US17481085

申请日：2021-09-21

申请人： The Regents of the University of California ,  University of Vienna

发明人： Jennifer A. Doudna ,  Martin Jinek ,  Krzysztof Chylinski ,  Emmanuelle Charpentier

IPC分类号： C12N15/90 ,  A01H6/46 ,  A01K67/027 ,  A61K38/46 ,  A61K48/00 ,  C12N9/22 ,  C12N15/10 ,  C12N15/11 ,  C12N15/113 ,  C12N15/63 ,  C12N15/70 ,  C12N15/74 ,  C12Q1/686 ,  H01L21/02 ,  H01L33/00

CPC分类号： C12N15/907 ,  A01H6/4684 ,  A01K67/027 ,  A61K38/465 ,  C12N9/22 ,  C12N15/102 ,  C12N15/111 ,  C12N15/113 ,  C12N15/63 ,  C12N15/70 ,  C12N15/746 ,  C12N15/90 ,  C12N15/902 ,  C12Q1/686 ,  H01L21/02312 ,  H01L21/02365 ,  H01L33/0075 ,  A61K48/00 ,  C12N2310/11 ,  C12N2310/13 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/31 ,  C12N2310/32 ,  C12N2310/33 ,  C12N2310/3519 ,  C12N2310/531 ,  C12N2800/80 ,  C12Y301/04

摘要： The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

公开(公告)号：US12102672B2

公开(公告)日：2024-10-01

申请号：US16959042

申请日：2018-12-21

申请人： INSTITUT GUSTAVE ROUSSY ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  UNIVERSITE PARIS-SACLAY ,  CENTRE HOSPITALIER UNIVERSITAIRE DE RENNES ,  UNIVERSITE DE RENNES

发明人： Laurence Zitvogel

IPC分类号： A61K39/12 ,  A61K35/76 ,  A61K45/00 ,  A61P35/00 ,  C07K14/005 ,  C07K14/74 ,  C12N5/0783 ,  C12N15/74 ,  C12Q1/02 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/543 ,  A61K39/00

CPC分类号： A61K39/12 ,  A61K35/76 ,  A61K45/00 ,  A61P35/00 ,  C07K14/005 ,  C07K14/70539 ,  C12N5/0636 ,  C12N15/746 ,  C12Q1/025 ,  C12Q1/6886 ,  G01N33/5091 ,  G01N33/54306 ,  A61K2039/5154 ,  A61K2039/523 ,  C12N2509/00 ,  C12N2795/10321 ,  C12N2795/10333 ,  C12N2795/10343 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2800/52

摘要： The present invention relates to the field of probiotic adjuvantization of anticancer treatments. In particular, the present invention concerns immunogenic sequences from a prophage present in bacteria identified as efficient adjuvants of cancer treatments. The invention provides bacterial compositions expressing immunogenic sequences from this prophage, immunogenic compositions comprising such sequences and methods using sequences from this prophage, for increasing the anticancer armamentarium.

公开(公告)号：US11844760B2

公开(公告)日：2023-12-19

申请号：US16813615

申请日：2020-03-09

申请人： SNIPR Technologies Limited

发明人： Jasper Clube ,  Morten Sommer ,  Christian Grøndahl ,  Eric Van Der Helm ,  Ruben Vazquez-Uribe

IPC分类号： A01N63/00 ,  A61K31/7105 ,  C12N15/113 ,  C12N15/74 ,  C12N15/70 ,  A61K31/711 ,  A61K45/06 ,  C12N15/10 ,  C12N9/16 ,  A61K35/74 ,  C12N15/90 ,  A01N63/50 ,  A01N63/60 ,  A61K48/00 ,  C12N1/20 ,  C12N7/00 ,  A61K35/00

CPC分类号： A61K31/7105 ,  A01N63/00 ,  A01N63/50 ,  A01N63/60 ,  A61K31/711 ,  A61K35/74 ,  A61K45/06 ,  A61K48/005 ,  C12N1/20 ,  C12N7/00 ,  C12N9/16 ,  C12N15/102 ,  C12N15/113 ,  C12N15/70 ,  C12N15/746 ,  C12N15/902 ,  A61K2035/11 ,  A61K2300/00 ,  C12N2310/20 ,  C12N2320/31 ,  C12N2795/00032 ,  C12N2795/10132 ,  Y02A50/30 ,  A61K31/7105 ,  A61K2300/00 ,  A61K31/711 ,  A61K2300/00 ,  A01N63/60 ,  A01N63/20 ,  A01N63/50 ,  A01N63/60

摘要： The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

公开(公告)号：US20230348918A1

公开(公告)日：2023-11-02

申请号：US18059689

申请日：2022-11-29

申请人： Intrexon Actobiotics NV

发明人： Pieter Rottiers ,  Lothar Steidler

IPC分类号： C12N15/74 ,  A61K35/744 ,  A61K39/395 ,  C07K16/28 ,  C07K14/54 ,  C07K14/62 ,  A61P3/10

CPC分类号： C12N15/746 ,  A61K35/744 ,  A61K39/3955 ,  A61P3/10 ,  C07K14/5428 ,  C07K14/62 ,  C07K16/2809 ,  C12N15/74

摘要： The current disclosure provides microorganisms, such as lactic acid bacteria (e.g., Lactococcus lactis) containing an exogenous nucleic acid encoding an IL-10 polypeptide and an exogenous nucleic acid encoding a T1D-specific antigen (e.g., a proinsulin) polypeptide, wherein both exogenous nucleic acids are integrated into the bacterial chromosome. Such microbial strains are suitable for human therapy. The disclosure further provides compositions (e.g., pharmaceutical compositions) methods of using the microorganisms and compositions, e.g., for the treatment of type 1 diabetes (T1D), including those with residual beta-cell function, e.g., recent-onset T1D. The microorganism may be administered orally, delivers the microorganism into the gastrointestinal tract, where it is released and expresses the bioactive polypeptides. The methods of the present disclosure are particularly well suited for subjects possessing residual beta-cell function, e.g., for subjects with recent-onset T1D.

公开(公告)号：US11773154B2

公开(公告)日：2023-10-03

申请号：US16010051

申请日：2018-06-15

申请人： Azitra Inc

发明人： Travis Michael Whitfill ,  Azim Momin Munivar

IPC分类号： C07K14/81 ,  A61P17/00 ,  C12N15/74 ,  A61K9/00 ,  A61K35/74

CPC分类号： C07K14/8135 ,  A61K9/0014 ,  A61K35/74 ,  A61P17/00 ,  C07K14/81 ,  C07K14/811 ,  C12N15/74 ,  C12N15/746

摘要： The present disclosure provides, inter alia, engineered microbes expressing recombinant LEKTI domains that are effective to treat or ameliorate the symptoms of Netherton Syndrome. In certain embodiments, compositions, methods, and kits are provided comprising LEKTI domain expressing microbes.

公开(公告)号：US11746362B2

公开(公告)日：2023-09-05

申请号：US17576290

申请日：2022-01-14

申请人： Duke University

发明人： Michael David Lynch ,  Zhixia Ye

IPC分类号： C12P7/42 ,  C12N9/04 ,  C12N9/02 ,  C12N9/06 ,  C12N9/10 ,  C12N15/74 ,  C12P13/06

CPC分类号： C12P7/42 ,  C12N9/001 ,  C12N9/0006 ,  C12N9/0008 ,  C12N9/0016 ,  C12N9/0051 ,  C12N9/1025 ,  C12N15/746 ,  C12P13/06

摘要： The present disclosure provides compositions and methods for rapid production of chemicals in genetically engineered microorganisms in a large scale. Also provided herein is a high-throughput metabolic engineering platform enabling the rapid optimization of microbial production strains. The platform, which bridges a gap between current in vivo and in vitro bio-production approaches, relies on dynamic minimization of the active metabolic network.

公开(公告)号：US20230218684A1

公开(公告)日：2023-07-13

申请号：US17995069

申请日：2021-03-29

申请人： NORTH CAROLINA STATE UNIVERSITY ,  COLORADO STATE UNIVERSITY RESEARCH FOUNDATION

发明人： Rodolphe Barrangou ,  Gregg A. Dean

IPC分类号： A61K35/744 ,  C12N1/20 ,  C12N15/74 ,  C07K14/165 ,  A61P31/14 ,  C07K14/14

CPC分类号： A61K35/744 ,  C12N1/20 ,  C12N15/746 ,  C07K14/165 ,  A61P31/14 ,  C07K14/14 ,  A61K2039/523

摘要： The present disclosure provides materials and methods related to engineered bacteria for use in vaccines. In particular, the present disclosure provides novel compositions and methods for generating vaccine compositions comprising bacteria (e.g., Lactobacillus) engineered to express immunogenic polypeptides and immunogenicity-enhancing adjuvant polypeptides to treat and/or prevent infection from a pathogenic organism (e.g., coronavirus).

公开(公告)号：US20190192584A1

公开(公告)日：2019-06-27

申请号：US16290581

申请日：2019-03-01

申请人： KIRIN HOLDINGS KABUSHIKI KAISHA

发明人： Daisuke FUJIWARA ,  Kenta Jonai ,  Tetsu Sugimura

IPC分类号： A61K35/744 ,  A23L33/135 ,  A23C19/032 ,  A23C9/123 ,  G01N33/68 ,  A61K35/747 ,  A61K31/711 ,  C12Q1/6809 ,  C12N15/74 ,  A23C19/06 ,  C12R1/01 ,  A61K9/00 ,  C12N1/20

CPC分类号： A61K35/744 ,  A23C9/123 ,  A23C9/1236 ,  A23C19/0323 ,  A23C19/062 ,  A23L33/135 ,  A23Y2240/41 ,  A61K9/0053 ,  A61K31/711 ,  A61K35/747 ,  C12N1/20 ,  C12N15/746 ,  C12Q1/6809 ,  C12R1/01 ,  G01N33/6866

摘要： This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as Lactococcus garvieae NBRC100934, Lactococcus lactis subsp. cremoris JCM16167, Lactococcus lactis subsp. cremoris NBRC100676, Lactococcus lactis subsp. hordniae JCM1180, Lactococcus lactis subsp. hordniae JCM11040, Lactococcus lactis subsp. lactis NBRC12007, Lactococcus lactis subsp. lactis NRIC1150, Lactococcus lactis subsp. lactis JCM5805, Lactococcus lactis subsp. lactis JCM20101, Leuconostoc lactis NBRC12455, Leuconostoc lactis NRIC1540, Pediococcus damnosus JCM5886, or Streptococcus thermophilus TA-45.

公开(公告)号：US20190106712A1

公开(公告)日：2019-04-11

申请号：US16201853

申请日：2018-11-27

申请人： Emmanuelle Charpentier ,  The Regents of the University of California ,  University of Vienna

发明人： Jennifer A. Doudna ,  Martin Jinek ,  Krzysztof Chylinski ,  Emmanuelle Charpentier

IPC分类号： C12N15/90 ,  A01K67/027 ,  C12N9/22 ,  A01H6/46 ,  C12N15/113 ,  C12N15/10 ,  C12N15/63 ,  C12N15/11 ,  C12N15/70 ,  C12N15/74 ,  A61K38/46

CPC分类号： C12N15/907 ,  A01H6/4684 ,  A01K67/027 ,  A61K38/465 ,  A61K48/00 ,  C12N9/22 ,  C12N15/102 ,  C12N15/111 ,  C12N15/113 ,  C12N15/63 ,  C12N15/70 ,  C12N15/746 ,  C12N15/90 ,  C12N15/902 ,  C12N2310/11 ,  C12N2310/13 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/31 ,  C12N2310/32 ,  C12N2310/33 ,  C12N2310/3519 ,  C12N2310/531 ,  C12N2800/80 ,  C12Y301/04

摘要： The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

公开(公告)号：US20190016762A1

公开(公告)日：2019-01-17

申请号：US15521418

申请日：2015-10-15

申请人： UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

发明人： YAIMA L. LIGHTFOOT ,  BIKASH SAHAY ,  MANSOUR MOHAMADZADEH

IPC分类号： C07K14/335 ,  C12N15/74 ,  A61K9/00 ,  A61K35/747 ,  A61K38/16

CPC分类号： C07K14/335 ,  A61K9/0053 ,  A61K35/747 ,  A61K38/13 ,  A61K38/164 ,  C12N1/20 ,  C12N15/746 ,  A61K2300/00

摘要： The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to decrease or eliminate the display of lipoteichoic acid (LTA), surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium. Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant L. acidophilus cells or a therapeutically effective amount of the isolated surface layer protein A (SlpA) or a non-naturally occurring derivative thereof. The recombinant L. acidophilus cells or SlpA isolated from L. acidophilus can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient. In an embodiment of the invention, the pharmaceutical composition is administered orally.